Vis enkel innførsel

dc.contributor.authorHofvind, Solveig
dc.contributor.authorKnutsvik, Gøril
dc.contributor.authorHolen, Åsne Sørlien
dc.contributor.authorTsuruda, Kaitlyn
dc.contributor.authorAkslen, Lars Andreas
dc.coverage.spatialNorwayen_US
dc.date.accessioned2022-06-01T09:28:43Z
dc.date.available2022-06-01T09:28:43Z
dc.date.created2021-07-06T12:41:43Z
dc.date.issued2021-06-22
dc.identifier.citationJournal of Medical Screening. 2021, 1-6.en_US
dc.identifier.issn0969-1413
dc.identifier.issn1475-5793
dc.identifier.urihttps://hdl.handle.net/11250/2997182
dc.description.abstractObjectives: To determine the frequency and discuss possible implications of early breast cancer with particularly good prognosis and defined by tumor diameter and cell proliferation. Setting: Detection of small and slowly growing tumors presents a challenge in breast cancer management, due to the risk of over-treatment. Here, we attempted to define a group of such tumors by combining small diameter (<10 mm, T1ab tumors) with low tumor cell proliferation (<10% Ki67 expression rate). These tumors were termed small low proliferation cancers (SLPC). Methods: Two population-based cohorts were studied: a small research series (n=534), and a nationwide registry-based series of prospectively collected routine data (n=8433). In the latter, we stratified by detection mode; screen-detected, interval, and breast cancers detected outside of screening. Patients were treated according to national guidelines at time of their diagnosis. For both cohorts, we compared tumor histopathology and risk of breast cancer death using a log-rank test for cases with SLPC versus non-SLPC. Results: In the research series (median follow-up 151 months), the frequency of SLPC was 10% (54/534), with one breast cancer death compared with 78 among the remaining 480 cases of non-SLPC (p=0.008). In the registry series (median follow-up 42 months), the frequency of SLPC was 10% (854/8433), with five deaths compared to 187 among the remaining 7579 cases (p=0.0004). Conclusions: SLPC was associated with very low risk of breast cancer death. Prospective randomized trials are needed to clarify whether less aggressive treatment could be a safe option for women with such early breast cancers.en_US
dc.description.sponsorshipThis work was supported by the University of Bergen and the Research Council of Norway through its Centres of Excellence funding scheme (project number 223250), and through the Helse Vest Research Fund. Kaitlyn Tsuruda is a PhD student funded by the Dam Foundation via the Norwegian Breast Cancer Society (2018/FO201362).en_US
dc.language.isoengen_US
dc.publisherSAGE Publicationsen_US
dc.relation.ispartofseriesJournal of Medical Screening;Volume: 29, issue: 1
dc.subjectEarly breast canceren_US
dc.subjectTumor diametersen_US
dc.subjectTumor proliferationen_US
dc.subjectTumor stagesen_US
dc.subjectPrognosesen_US
dc.titleDetection and significance of small and low proliferation breast canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.fulltextpostprint
cristin.qualitycode1
dc.identifier.doihttps://doi.org/10.1177/09691413211023970
dc.identifier.cristin1920479
dc.source.journalJournal of Medical Screeningen_US
dc.source.volume29en_US
dc.source.issue1en_US
dc.source.pagenumber14en_US
dc.relation.projectNorges forskningsråd: 223250en_US
dc.relation.projectStiftelsen Dam: 2018/FO201362en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel